Wesley M. Stansberry

Wesley M. Stansberry

Auto-generated profile, based on publicly available information

Wesley M. Stansberry

Department of Medicine, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
KCKimberly S. Collins
Kimberly S. Collins
VPVictoria M. Pratt
Victoria M. Pratt
WSWesley M. Stansberry
Wesley M. Stansberry
EMElizabeth B. Medeiros
Elizabeth B. Medeiros
KKKarthik Kannegolla
Karthik Kannegolla
MEMichael T. Eadon
Michael T. Eadon
Hypertension and chronic kidney disease are inextricably linked. Hypertension is a well-recognized contributor to chronic kidney disease progression and, in turn, renal disease potentiates hypertension. A generalized approach to drug selection and dosage has not proven effective in managing these conditions, in part, because patients with heterogeneous kidney disease and hypertension etiologies are frequently grouped according to functional or severity classifications. Genetic testing may serve as an important tool in the armamentarium of clinicians who embrace precision medicine. Increasing scientific evidence has supported the utilization of genomic information to select efficacious antihypertensive therapy and understand hereditary contributors to chronic kidney disease progression. Given the wide array of antihypertensive agents available and diversity of genetic renal disease predictors, a panel-based approach to genotyping may be an efficient and economic means of establishing an individualized blood pressure response profile for patients with various forms of chronic kidney disease and hypertension. In this manuscript, we discuss the validation process of a Clinical Laboratory Improvement Amendments-approved genetic test to relay information on 72 genetic variants associated with kidney disease progression and hypertension therapy. These genomic-based interventions, in addition to routine clinical data, may help inform physicians to provide personalized therapy.

1 November 2018 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Closed access
WSWesley M. Stansberry
Wesley M. Stansberry
MSMarelize Swart
Marelize Swart
EMElizabeth B. Medeiros
Elizabeth B. Medeiros
TSTodd C. Skaar
Todd C. Skaar
VPVictoria Pratt
Victoria Pratt
Aims: To validate a laboratory-developed test for the nucleoside transporter, SLC28A3, which has been associated with an increased risk of anthracycline-induced cardiomyopathy. Methods: We used Taqman® allele discrimination to test for two variants of the SLC28A3 gene: rs7853758 (c.1381C>T) and rs885004 (c.862-360C>T). Results: During the validation process, we noted that several DNA samples obtained from the Coriell Cell Repository (Camden, NJ) were positive for both the c.1381 C > T and c.862-360C>T variants and another variant allele for either c.1381 C > T or c.862-360C>T (e.g., c.1381C>T homozygous/c.862-360C>T heterozygous, c.1381C>T homozygous/c.862-360C>T homozygous). We used de-identified DNA samples from trios of family members (mother, father, and child) to establish that the c.1381 C > T and c.862-360C>T variant alleles could be inherited in cis on the same chromosome. Conclusions: Samples containing three variant alleles suggest that the c.1381 C > T and c.862-360C>T are in cis on the chromosome in some individuals and may have implications when calculating anthracycline-induced cardiomyopathy risk. In this study, we confirm a novel haplotype of SLC28A3 using familial studies.

1 May 2019 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
MSMarelize Swart
Marelize Swart
WSWesley M. Stansberry
Wesley M. Stansberry
VPVictoria Pratt
Victoria Pratt
EMElizabeth B. Medeiros
Elizabeth B. Medeiros
PKPatrick J. Kiel
Patrick J. Kiel
TSTodd C. Skaar
Todd C. Skaar